Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis

Mucosal Immunology

Volumn 9, Issue 4, 2016, Pages 950-959

  Mora Buch, R ^a   Dotti, I ^a   Planell, N ^a,b   Calderon Gomez E ^a   Jung, P ^c   Masamunt, M C ^a   Llach, J ^b   Ricart, E ^a   Batlle, E ^c,d   Panes J ^a   Salas, A ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; WNT PROTEIN; IL1R2 PROTEIN, HUMAN; INTERLEUKIN 1BETA;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; EPITHELIUM CELL; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IL1R2 GENE; INTESTINE MUCOSA; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; REGULATORY MECHANISM; REMISSION; ULCERATIVE COLITIS; UPREGULATION; ADULT; AGED; CELL CULTURE; FEMALE; FOLLOW UP; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; T LYMPHOCYTE; YOUNG ADULT;

ADULT; AGED; BETA CATENIN; CELLS, CULTURED; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; HOMEOSTASIS; HUMANS; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1 TYPE II; REMISSION, SPONTANEOUS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UP-REGULATION; WNT PROTEINS; YOUNG ADULT;

EID: 84975862642     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2015.108     Document Type: Article

References (44)

1. Ordas, I., Eckmann, L., Talamini, M., Baumgart, D.C. & Sandborn, W.J. Ulcerative colitis. Lancet 380, 1606-1619 (2012).
2. Planell, N. et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 62, 967-976 (2013).
3. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
4. Garlanda, C., Dinarello, C.A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003-1018 (2013).
5. Roman, J. et al. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. Inflamm. Bowel Dis. 19, 221-229 (2013).
6. Leal, R.F. et al. Identification of inflammatorymediators in patients withCrohns disease unresponsive to anti-TNFalpha therapy. Gut 64, 233-242 (2014).
7. Lopetuso, L.R., Chowdhry, S. & Pizarro, T.T. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front. Immunol. 4, 181 (2013).
8. Colotta, F. et al. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 261, 472-475 (1993).
9. Bersudsky, M. et al. Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut 63, 598-609 (2014).
10. Dinarello, C.A., Simon, A. & van der Meer, J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633-652 (2012).
11. Rauschmayr, T., Groves, R.W. & Kupper, T.S. Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc. Natl Acad. Sci. USA 94, 5814-5819 (1997).
12. Bessis, N. et al. The type II decoy receptor of IL-1 inhibits murine collageninduced arthritis. Eur. J. Immunol. 30, 867-875 (2000).
13. Caraux, A. et al. Circulating human B and plasma cells. Age-Associated changes in counts and detailed characterization of circulating normal CD138-And CD138+ plasmacells. Haematologica 95, 1016-1020 (2010).
14. Jung, P. et al. Isolation and in vitro expansion of human colonic stem cells. Nat. Med. 17, 1225-1227 (2011).
15. Clevers, H. & Nusse, R. Wnt/beta-catenin signaling and disease. Cell 149, 1192-1205 (2012).
16. Zahn, A. et al. Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis. BMC Gastroenterol. 9, 13 (2009).
17. Egesten, A. et al. The proinflammatory CXC-chemokines GRO-Alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int. J. Colorectal Dis. 22, 1421-1427 (2007).
18. Kaser, A. et al. Increased expression of CCL20 in human inflammatory bowel disease. J. Clin. Immunol. 24, 74-85 (2004).
19. Globig, A.M. et al. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-gamma+IL-17+ coproducing CD4+ T cells in active inflammatory bowel disease. Inflamm. Bowel Dis. 20, 2321-2329 (2014).
20. Duhen, T. & Campbell, D.J. IL-1beta promotes the differentiation of polyfunctional human CCR6+CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes. J. Immunol. 193, 120-129 (2014).
21. Neurath, M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329-342 (2014).
22. Gustot, T. et al. Profile of soluble cytokine receptors in Crohns disease. Gut 54, 488-495 (2005).
23. Liang, D., Ma, W., Yao, C., Liu, H. & Chen, X. Imbalance of interleukin 18 and interleukin 18 binding protein in patients with lupus nephritis. Cell. Mol. Immunol. 3, 303-306 (2006).
24. Serhan, C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101 (2014).
25. Fedorak, R.N. et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohns disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119, 1473-1482 (2000).
26. van de Veerdonk, F.L., Netea, M.G., Dinarello, C.A. & van der Meer, J.W. Anakinra for the inflammatory complications of chronic granulomatous disease. Neth. J. Med. 69, 95 (2011).
27. Vong, L., Ferraz, J.G., Panaccione, R., Beck, P.L. & Wallace, J.L. A proresolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-Term remission from ulcerative colitis. Proc. Natl Acad. Sci. USA 107, 12023-12027 (2010).
28. Vong, L. et al. Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One 7, e39244 (2012).
29. Treton, X. et al. Altered endoplasmic reticulum stress affects translation in inactive colon tissue from patients with ulcerative colitis. Gastroenterology 141, 1024-1035 (2011).
30. Gustafsson, J.K., Hansson, G.C. & Sjovall, H. Ulcerative colitis patients in remission have an altered secretory capacity in the proximal colon despite macroscopically normal mucosa. Neurogastroenterol. Motil. 24, e381-e391 (2012).
31. Fasseu, M. et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One, 5 (2010).
32. Ludwiczek, O. et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin. Exp. Immunol. 138, 323-329 (2004).
33. McMahan, C.J. et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 10, 2821-2832 (1991).
34. Lukiw, W.J., Martinez, J., Pelaez, R.P. & Bazan, N.G. The interleukin-1 type 2 receptor gene displays immediate early gene responsiveness in glucocorticoid-stimulated human epidermal keratinocytes. J. Biol. Chem. 274, 8630-8638 (1999).
35. Penton-Rol, G. et al. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J. Immunol. 162, 2931-2938 (1999).
36. Orlando, S. et al. TNF-Alpha, unlike other pro-And anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells. J. Immunol. 158, 3861-3868 (1997).
37. Brown, J.B. et al. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology 138, 605 e591-e593 (2010).
38. Seldenrijk, C.A., Morson, B.C., Meuwissen, S.G., Schipper, N.W., Lindeman, J. & Meijer, C.J. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut 32, 1514-1520 (1991).
39. Jauregui-Amezaga, A. et al. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: A prospective study. Inflamm. Bowel Dis. 20, 1187-1193 (2014).
40. de Luca, A. et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc. Natl Acad. Sci. USA 111, 3526-3531 (2014).
41. Li, Y., Wang, L., Pappan, L., Galliher-Beckley, A. & Shi, J. IL-1beta promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol. Cancer 11, 87 (2012).
42. Wang, Y. et al. Neutrophil infiltration favors colitis-Associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol. 7, 1106-1115 (2014).
43. Dinarello, C.A. Why not treat human cancer with interleukin-1 blockade?. Cancer Metastasis Rev. 29, 317-329 (2010).
44. Schroeder, K.W., Tremaine, W.J. & Ilstrup, D.M. Coated oral 5-Aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625-1629 (1987).